US court sides with Astra on SEROQUEL

Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.

Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.

The US District Court for the District of New Jersey also ruled that generic drugs makers Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals, Torrent Pharma, Mylan Pharmaceuticals and Mylan have all infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.